$PMN News

ProMIS Neurosciences Appoints Seasoned Alzheimer’s and Neuroscience Executive Ivana Rubino, Ph.D., as Chief Commercial Officer

ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September

Guggenheim Maintains Buy on ProMIS Neurosciences, Raises Price Target to $100

ProMIS Neurosciences Inc (PMN) (Q2 2026) Earnings Call Highlights: Zero ARIA-E Cases and ...

Promis Neurosciences Q2 Earnings Call Highlights

ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

ProMIS Neurosciences Reports Q2 2026 Results: Full Earnings Call Transcript

ProMIS Neurosciences Q2 EPS $(1.28) Beats $(1.38) Estimate

ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026

Guggenheim Maintains Buy on ProMIS Neurosciences, Raises Price Target to $69

Promis Reports No ARIA-E in PMN310 Alzheimer’s Trial Interim Data

Small-Cap ProMIS Neurosciences Says Lead Drug Shows Encouraging Action in Early Alzheimer's Study

ProMIS Neurosciences Shares Climb on Positive Interim Alzheimer’s Trial Safety Results

Chardan Capital Maintains Buy on ProMIS Neurosciences, Raises Price Target to $33

ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial

ProMIS Neurosciences Announces Six-Month Interim Safety And Biomarker Results From Its PRECISE-AD Phase 1B Trial Of PMN310 In Patients With Mild Cognitive Impairment Due To Alzheimer’s; Early Biomarker Movement Consistent With Target Engagement

ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease

Chardan Capital Initiates Coverage On ProMIS Neurosciences with Buy Rating, Announces Price Target of $20

ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026

ProMIS Neurosciences' PMN310 Shows Dose-Dependent Reduction Of Amyloid-Beta Oligomers In Healthy Volunteers, With Six-Month Phase 1b Interim Data Expected Soon